Go to Noxopharm website
Home
About Us
About Pharmorage
About Noxopharm
About Hudson Institute of Medical Research
Our Team
Our Science
Our Technology Platforms
Our Drug Pipeline
The Innate Immune System and Autoimmunity
Improving mRNA Therapeutics and Vaccines
Research
Our Collaborators
About Noxopharm
About Hudson Institute of Medical Research
About John Curtin School of Medical Research
Related Research and Selected Relevant Literature
Publications and Conferences
Technical Glossary and FAQs
Company News
NOX ASX Announcements
Recent Global M & A Activity
Media
Newsletters
Other Company News
Upcoming Events
Presentation and Interviews
Contact
Contact Us
Email Alerts
NOX ASX Announcements
Media
Other Company News
Upcoming Events
Recent Posts
Noxopharm collaborators at Hudson confirm the relevance of TLR7 activation in Lupus validating the great potential of Noxopharm’s in-licenced molecules, comprising a new class of TLR7 inhibitors.
Sequence-dependent inhibition of cGAS and TLR9 DNA sensing by 2′-O-methyl gapmer oligonucleotides
Rational design of antisense oligonucleotides modulating the activity of TLR7/8 agonists
Inhibition of STING Signaling with Flavonoid Compounds
Characterization of 2’-O-methyl oligonucleotides that potently inhibit cGAS and TLR9 DNA sensing
Categories
Conference presentations and posters
Media
Peer-reviewed journal articles
Publications
Cancer drug investigated as anti-inflammatory for lethal conditions including COVID-19
1 April 2020
by Pharmorage
Read More
Page:
1
